A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
Johanna C. Bendell(Dana-Farber Cancer Institute), Anthony A. Meluch(Tennessee Oncology), Richard LoCicero(Northeast Georgia Medical Center), Cassie M. Lane(Sarah Cannon), David Waterhouse(Oncology Hematology Care), Chris Earwood(Sarah Cannon), Ahmed Zakari(Florida Hospital Cancer Institute), Mark A. Moskowitz(Boston University), Ralph V. Boccia(Center for Cancer and Blood Disorders), James D. Peyton(Tennessee Oncology), Victor G. Gian(Tennessee Oncology), Andrew Lipman(Sarah Cannon)
Cited by 20
Related Papers
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
|Annals of Oncology|2020|1.5k
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
|Breast Cancer Research and Treatment|2017|761
Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
|Journal of Clinical Oncology|2011|684
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
|The Lancet Oncology|2012|541
Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia
|New England Journal of Medicine|2010|425